Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S345000, C514S352000, C514S354000, C514S357000, C546S272100, C546S272400, C546S272700, C546S275400, C546S290000, C546S304000, C546S313000, C546S314000, C546S329000, C546S339000
Reexamination Certificate
active
07105549
ABSTRACT:
This invention relates aryl substituted pyridines of Formula I:or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1–R4are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
REFERENCES:
patent: 3149109 (1964-09-01), Rorig et al.
patent: 3502673 (1970-03-01), Hepworth et al.
patent: 3631036 (1971-12-01), Kim et al.
patent: 3660414 (1972-05-01), Hardtmann et al.
patent: 3709888 (1973-01-01), Hardtmann et al.
patent: 3886167 (1975-05-01), Ash et al.
patent: 3940404 (1976-02-01), Ash et al.
patent: 4133956 (1979-01-01), Abdulla et al.
patent: 4260621 (1981-04-01), Roch et al.
patent: 4293552 (1981-10-01), Miesel
patent: 4332809 (1982-06-01), Honma et al.
patent: 4364956 (1982-12-01), Clark et al.
patent: 4530842 (1985-07-01), Bormann
patent: 4698091 (1987-10-01), Brunner et al.
patent: 4701208 (1987-10-01), Los
patent: 4762835 (1988-08-01), Whittle et al.
patent: 4769462 (1988-09-01), Los
patent: 4783466 (1988-11-01), Katoh et al.
patent: 4912218 (1990-03-01), Coyle et al.
patent: 4920119 (1990-04-01), Attwood et al.
patent: 4962109 (1990-10-01), McDonald et al.
patent: 4968702 (1990-11-01), Poletto et al.
patent: 5010200 (1991-04-01), McDonald et al.
patent: 5084462 (1992-01-01), Ackerman et al.
patent: 5116989 (1992-05-01), Hale et al.
patent: 5136080 (1992-08-01), Miller et al.
patent: 5250533 (1993-10-01), Heinemann et al.
patent: 5340701 (1994-08-01), Desobry
patent: 5389632 (1995-02-01), Bru-Magniez et al.
patent: 5403934 (1995-04-01), Batchelor et al.
patent: 5405553 (1995-04-01), Terada et al.
patent: 5418233 (1995-05-01), Linz et al.
patent: 5563268 (1996-10-01), Linz et al.
patent: 5587380 (1996-12-01), Miller et al.
patent: 5591746 (1997-01-01), Miller et al.
patent: 5597827 (1997-01-01), Miller et al.
patent: 5597828 (1997-01-01), Miller et al.
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5635507 (1997-06-01), Miller et al.
patent: 5684005 (1997-11-01), Miller et al.
patent: 5712276 (1998-01-01), Miller et al.
patent: 5744492 (1998-04-01), Kohn et al.
patent: 5756524 (1998-05-01), Riordan et al.
patent: 5824624 (1998-10-01), Kleeman et al.
patent: 5849758 (1998-12-01), Kleeman et al.
patent: 5985886 (1999-11-01), Elliott et al.
patent: 6008161 (1999-12-01), Kleeman et al.
patent: 6057346 (2000-05-01), Kohn et al.
patent: 6066597 (2000-05-01), Kleeman et al.
patent: 6127371 (2000-10-01), Elliott et al.
patent: 6335354 (2002-01-01), Hogenkamp
patent: 6414011 (2002-07-01), Hogenkamp et al.
patent: 2001/0044428 (2001-11-01), Hogenkamp
patent: 2002/0006947 (2002-01-01), Hogenkamp et al.
patent: 2002/0040025 (2002-04-01), Hogenkamp et al.
patent: 2003/0236273 (2003-12-01), Goehring et al.
patent: 2004/0116388 (2004-06-01), Armistead et al.
patent: 2004/0192691 (2004-09-01), Hogenkamp et al.
patent: 30 12 597 (1980-10-01), None
patent: 32 39 573 (1983-05-01), None
patent: 32 45 950 (1983-07-01), None
patent: 0 096 657 (1983-12-01), None
patent: 0 123 700 (1984-11-01), None
patent: 0 200 024 (1986-11-01), None
patent: 0 271 195 (1988-06-01), None
patent: 0 362 578 (1990-04-01), None
patent: 0 389 236 (1990-09-01), None
patent: 0 389 236 (1991-02-01), None
patent: 0 428 268 (1991-05-01), None
patent: 0 446 604 (1991-09-01), None
patent: 0 446 604 (1992-02-01), None
patent: 0 480 258 (1992-04-01), None
patent: 0 480 258 (1992-09-01), None
patent: 0 507 962 (1992-10-01), None
patent: 0 518 798 (1992-12-01), None
patent: 0 550 900 (1993-07-01), None
patent: 0 518 798 (1994-12-01), None
patent: 0 706 795 (1996-04-01), None
patent: 1 052 238 (2000-11-01), None
patent: 1477021 (1967-04-01), None
patent: 1536093 (1967-09-01), None
patent: 2 095 240 (1982-09-01), None
patent: 190 839 (1986-11-01), None
patent: 206 202 (1987-07-01), None
patent: 56-104883 (1981-08-01), None
patent: 63-20234 (1988-04-01), None
patent: 2-52360 (1990-02-01), None
patent: 7-76542 (1995-03-01), None
patent: 92004354 (1995-03-01), None
patent: 1790172 (1995-05-01), None
patent: 96101815 (1998-03-01), None
patent: 2171256 (2001-07-01), None
patent: WO 92/06085 (1992-04-01), None
patent: WO 93/10114 (1993-05-01), None
patent: WO 95/19358 (1995-07-01), None
patent: WO 96/40628 (1996-12-01), None
patent: WO 98/37068 (1998-08-01), None
patent: WO 98/47869 (1998-10-01), None
patent: WO 99/31062 (1999-06-01), None
patent: WO 99/31088 (1999-06-01), None
patent: WO 99/32468 (1999-07-01), None
patent: WO 99/38829 (1999-08-01), None
patent: WO 00/32192 (2000-06-01), None
patent: WO 00/39087 (2000-07-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 00/39087 (2000-11-01), None
patent: WO 01/47904 (2001-07-01), None
patent: WO 01/53288 (2001-07-01), None
patent: WO 01/68612 (2001-09-01), None
patent: WO-68612 (2001-09-01), None
patent: WO 01/68612 (2002-03-01), None
patent: WO 02/24679 (2002-03-01), None
“Ion Channels, Transmitters, Receptors, and Disease: Sodium Channels,” internet article, (2005), http://www.neuro.wustl.edu
euromuscular/mother/chan.html, pp. 5-10.
“Alzheimer's Disease, Parkinson's Disease, and Related Brain Disorders: Brief Overview for Patients and Caregivers,” internet article by Dr. John Q. Trojanowski, http://www.uphs.upenn.edu/cndr/Research/pages/ADPD.html, pp. 1-5.
Gomez-Parra, V., et al., “New Cardiotonic Agents Related to Amrinone: Synthesis of 1,2-Dihydro-5-arylpyridin-2-ones,”Arch. Pharm. 325:483-490, VCH Verlagsgesellschaft mbH (1992).
Dialog File 351, Accession No. 3689403, Derwent WPI English language abstract for German Patent Publication No. DE 32 39 573 A1, Derwent Information Ltd. (1983).
Dialog File 351, Accession No. 14030103, Derwent WPI English language abstract for WIPO Patent Publication No. WO 01/47904 A1, Derwent Information Ltd. (Jul. 2001).
Dialog File 351, Accession No. 14038004, Derwent WPI English language abstract for WIPO Patent Publication No. WO 01/53288 A1, Derwent Information Ltd. (Jul. 2001).
Aggarwal, V., et al., “Reaction of α-KetoketeneS,N-Acetals with Cyanoacetamide: A New General Method for Substituted and Fused 4-(N-Alkylamino-,N-Arylamino-, orN-Morpholino)-3-cyano-2(1H)-pyridones,”Synthesis3:214-216, Georg Thieme Verlag (1982).
Akopian, A.N., et al., “The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways,”Nat. Neurosci. 2:541-548, Nature America Inc. (1999).
Al-Omran, F. and Al-Awadi, N., “Studies of Polyfunctionally Substituted Heteroaromatics: Synthesis of New Polyfunctionally Substituted Azabiaryls,”J. Chem. Res. Synop. 10:392-393, The Royal Society of Chemistry (1995).
Amine, M.S., “Utilities of 4-(4′-Benzyl Phenyl)-6-Arylpyrimidine-2-Thiones for the Synthesis of Biologically Active Condensed and Non-Condensed Heterocycles,”Egypt. J. Chem. 41:267-276, The National Information and Documentation Centre (1998).
Backonja, M., et al., “Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus,”J. Am. Med. Assoc. 280:1831-1836, American Medical Association (1998).
Baker, M.D. and Wood, J.N., “Involvement of Na+channels in pain pathways,”Trends Pharm. Sci. 22:27-31, Elsevier Science Ltd. (Jan. 2001).
Baldwin, J.E., et al., “Concise Syntheses of Acromelic Acid A andAllo-Acromelic Acid A,”Tetrahedron Lett. 39:707-710, Pergamon (1998).
Bennett, G.J., “Neuropathic Pain: New Insights, New Interventions,”Hosp. Prac. 33:95-98, 101-104, 107-110, 113-114, The McGraw-Hill Companies (1998).
Bensimon, G., et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis,”New Eng. J. Med. 3
Goehring R. Richard
Shao Bin
Sun Qun
Victory Samuel F
Coppins Janet L
Euro-Celtique S.A.
Saeed Kamal A.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Aryl substituted pyridines and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl substituted pyridines and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted pyridines and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591929